Why HUTCHMED Stock Is Moving Higher Friday

HUTCHMED HCM stock is trading higher on Friday following the company’s announcement that its New Drug Application (NDA) for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status.

The Details: The China National Medical Products Administration granted priority review for the treatment for certain types of lymphoma. The NDA is based on a Phase 2 study in China and clinical trials conducted by Epizyme outside of China.

Tazemetostat is already approved by the Food and Drug Administration for relapsed or refractory follicular lymphoma and certain cases of advanced epithelioid sarcoma. Furthermore, the treatment is authorized by the Japan Ministry of Health, Labour and Welfare for the same types of lymphoma.

How To Buy HUTCHMED Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in HUTCHMED (China)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

Related Link: What’s Going On With Johnson and Johnson Shares Friday?

HCM Price Action: HUTCHMED stock is trading 5.65% higher at $18.51 as of Friday morning per data from Benzinga Pro.

Image: 5620566 from Pixabay.